The Efficacy of Oral Ergocalciferol on Changes in Parathyroid Hormone (iPTH) and One-Year Survival and Hemodialysis Factors of Patients with Chronic Renal Failure and Vitamin D Deficiency under Hemodialysis

Document Type : Original Article (s)

Authors

1 Assistant Professor, Department of Internal Disease, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

2 Associate Professor, Department of Internal Disease, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

3 Internist, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

4 Obstetrics and Gynecologist, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: The use of vitamin D supplementation in patients with diabetes mellitus and low levels of 25 (OH) vitamin D, especially in patients under long-term hemodialysis, is common; but the safety and efficacy of vitamin D supplementation in these patients remains uncertain. The aim of this study was to examine the efficacy of oral vitamin D supplementation (Ergocalciferol) on changes in intact parathyroid hormone (iPTH) and hemodialysis factors in patients with end-stage renal disease (ESRD).Methods: A clinical trial study was performed on 110 patients under hemodialysis referred to dialysis center of Rasoul Akram hospital, Tehran, Iran. The patients were randomly assigned into two equal groups of case and control, after informed consent. The case group received omega-3 with vitamin D (50,000 units) capsules, and the control group was only treated with omega-3 capsules weekly for six weeks. After 12 weeks from the start of the study, they were re-evaluated in the same laboratory, and the results were compared between the groups.Findings: The serum level of iPTH was significantly different between the two groups after the intervention (P < 0.001). The findings also showed that serum levels of calcium (P = 0.022) and vitamin D (P < 0.001) had a significant difference between the two groups after the intervention. On the other hand, serum albumin, phosphorus, and creatinine were not significantly different between the two groups, before and after intervention (P > 0.050).Conclusion: According to the results of this study, the administration of Ergocalciferol leads to a decrease in the serum level of iPTH, and increase in serum calcium and vitamin D in patients under hemodialysis; but does not change the serum level of albumin, phosphorus, creatinine, as well as mortality. So, the length of follow up, and the factors affecting mortality should be investigated to determine the effect of vitamin D on these patients.

Keywords

References

  1. St John A, Thomas MB, Davies CP, Mullan B, Dick I, Hutchison B, et al. Determinants of intact parathyroid hormone and free 1,25-dihydroxyvitamin D levels in mild and moderate renal failure. Nephron 1992; 61(4): 422-7.
  2. Padilla J, Krasnoff J, Da Silva M, Hsu CY, Frassetto L, Johansen KL, et al. Physical functioning in patients with chronic kidney disease. J Nephrol 2008; 21(4): 550-9.
  3. Leikis MJ, McKenna MJ, Petersen AC, Kent AB, Murphy KT, Leppik JA, et al. Exercise performance falls over time in patients with chronic kidney disease despite maintenance of hemoglobin concentration. Clin J Am Soc Nephrol 2006; 1(3): 488-95.
  4. Gordon PL, Sakkas GK, Doyle JW, Shubert T, Johansen KL. Relationship between vitamin D and muscle size and strength in patients on hemodialysis. J Ren Nutr 2007; 17(6): 397-407.
  5. Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(3): 1-201.
  6. Endo I, Inoue D, Mitsui T, Umaki Y, Akaike M, Yoshizawa T, et al. Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology 2003; 144(12): 5138-44.
  7. Dzik K, Skrobot W, Flis DJ, Karnia M, Libionka W, Kloc W, et al. Vitamin D supplementation attenuates oxidative stress in paraspinal skeletal muscles in patients with low back pain. Eur J Appl Physiol 2018; 118(1): 143-51.
  8. Girgis CM, Clifton-Bligh RJ, Hamrick MW, Holick MF, Gunton JE. The roles of vitamin D in skeletal muscle: Form, function, and metabolism. Endocr Rev 2013; 34(1): 33-83.
  9. Bikle DD. Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol 2014; 21(3): 319-29.
  10. Wijnia JW, Wielders JP, Lips P, van de Wiel A, Mulder CL, Nieuwenhuis KG. Is vitamin D deficiency a confounder in alcoholic skeletal muscle myopathy? Alcohol Clin Exp Res 2013; 37(Suppl 1): E209-E215.
  11. Bunout D, Barrera G, Leiva L, Gattas V, de la Maza MP, Avendano M, et al. Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects. Exp Gerontol 2006; 41(8): 746-52.
  12. Sato Y, Iwamoto J, Kanoko T, Satoh K. Low-dose vitamin D prevents muscular atrophy and reduces falls and hip fractures in women after stroke: A randomized controlled trial. Cerebrovasc Dis 2005; 20(3): 187-92.
  13. Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, et al. Vitamin D and human health: Lessons from vitamin D receptor null mice. Endocr Rev 2008; 29(6): 726-76.
  14. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357(3): 266-81.
  15. Gallieni M, Kamimura S, Ahmed A, Bravo E, Delmez J, Slatopolsky E, et al. Kinetics of monocyte 1 alpha-hydroxylase in renal failure. Am J Physiol 1995; 268(4 Pt 2): F746-F753.
  16. Isakova T, Gutierrez OM, Patel NM, Andress DL, Wolf M, Levin A. Vitamin D deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions. J Ren Nutr 2011; 21(4): 295-302.
  17. Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S. Vitamin D status and mortality risk in CKD: A meta-analysis of prospective studies. Am J Kidney Dis 2011; 58(3): 374-82.
  18. Heaf JG, Molsted S, Harrison AP, Eiken P, Prescott L, Eidemak I. Vitamin D, surface electromyography and physical function in uraemic patients. Nephron Clin Pract 2010; 115(4): c244-c250.
  19. Agarwal G, Vasquez K, Penagaluru N, Gelfond J, Qunibi WY. Treatment of vitamin D deficiency/insufficiency with ergocalciferol is associated with reduced vascular access dysfunction in chronic hemodialysis patients. Hemodial Int 2015; 19(4): 499-508.
  20. Al-Aly Z, Qazi RA, Gonzalez EA, Zeringue A, Martin KJ. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis 2007; 50(1): 59-68.
  21. Kidir V, Ersoy I, Altuntas A, Gultekin F, Inal S, Dagdeviren BH, et al. Effect of cholecalciferol replacement on vascular calcification and left ventricular mass index in dialysis patients. Ren Fail 2015; 37(4): 635-9.
  22. Fanari Z, Hammami S, Hammami MB, Hammami S, Abdellatif A. Vitamin D deficiency plays an important role in cardiac disease and affects patient outcome: Still a myth or a fact that needs exploration? J Saudi Heart Assoc 2015; 27(4): 264-71.
  23. Kandula P, Dobre M, Schold JD, Schreiber MJ, Jr., Mehrotra R, Navaneethan SD. Vitamin D supplementation in chronic kidney disease: A systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 2011; 6(1): 50-62.
  24. Bansal B, Bansal S, Mithal A, Kher V, Marwaha R. Vitamin D deficiency in hemodialysis patients. Indian J Endocrinol Metab 2012; 16(2): 270-3.
  25. Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int 2009; 20(11): 1807-20.
  26. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: A negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 2004; 89-90(1-5): 387-92.
  27. Sun J, Kong J, Duan Y, Szeto FL, Liao A, Madara JL, et al. Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor. Am J Physiol Endocrinol Metab 2006; 291(2): E315-E322.
  28. Tomaschitz A, Pilz S, Ritz E, Grammer T, Drechsler C, Boehm BO, et al. Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chim Acta 2010; 411(17-18): 1354-60.
  29. Li YC. Renoprotective effects of vitamin D analogs. Kidney Int 2010; 78(2): 134-9.
Journal of Isfahan Medical School
Volume 37, Issue 518 - Serial Number 518
January and February 2019
Pages 190-197

Files

History

  • Receive Date: 22 January 2019
  • Revise Date: 26 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics